Dandan Li^*, Changjun He^†, Junfeng Wang^†, Yanbo Wang^†, Jianlong Bu^†, Xianglong Kong^†, Dawei Sun^†

Oncology Research, Vol.26, No.3, pp. 385-400, 2018, DOI:10.3727/096504017X14973124850905

Abstract Many studies have shown that downregulation of miR-138 occurs in a variety of cancers including non-small cell lung cancer (NSCLC). However, the precise mechanisms of miR-138 in NSCLC have not been well clarified. In this study, we investigated the biological functions and molecular mechanisms of miR-138 in NSCLC cell lines, discussing whether it could turn out to be a therapeutic biomarker of NSCLC in the future. In our study, we found that miR-138 is downregulated in NSCLC tissues and cell lines. Moreover, the low level of miR-138 was associated with increased expression of SOX4 in… More >

Kejun Wang^*1, Lin Yan^*1, Fen Lu^†

Oncology Research, Vol.27, No.2, pp. 157-163, 2019, DOI:10.3727/096504018X15190861873459

Abstract miR-363-3p has been shown to suppress tumor growth and metastasis in various human cancers. However, the function of miR-363-3p in osteosarcoma (OS) has not been determined. In our study, we found that the expression of miR-363-3p was significantly downregulated in OS tissues compared with adjacent normal tissues. miR-363-3p expression was associated with the poor overall survival rate of OS patients. Moreover, we found that overexpression of miR-363-3p markedly inhibited the proliferation, migration, and invasion of U2OS and MG63 cells. Moreover, we found that SOX4 was a direct target of miR-363-3p in OS cells. Overexpression of More >